Biomaterials:新型药物载体能定向将青蒿素运载进入肿瘤细胞

2014-07-04 MedSci MedSci原创

中国科学院强磁场科学中心双聘研究员陈乾旺、中国科学技术大学生命科学学院教授郭振副、安徽医科大学副主任医师王海宝三课题组合作,利用肿瘤细胞内环境的调控,发展了具有pH响应性的多功能药物载体,它能够将疏水药物青蒿素输送到肿瘤细胞内,同时释放出可作为青蒿素抗癌的诱导剂的Fe2+,从而大大提高了抗癌药效。相关研究在线发表在《生物材料》(Biomaterials)上。目前临床上广泛使用的抗癌药物仍为人工合成

中国科学院强磁场科学中心双聘研究员陈乾旺、中国科学技术大学生命科学学院教授郭振副、安徽医科大学副主任医师王海宝三课题组合作,利用肿瘤细胞内环境的调控,发展了具有pH响应性的多功能药物载体,它能够将疏水药物青蒿素输送到肿瘤细胞内,同时释放出可作为青蒿素抗癌的诱导剂的Fe2+,从而大大提高了抗癌药效。相关研究在线发表在《生物材料》(Biomaterials)上。

目前临床上广泛使用的抗癌药物仍为人工合成的,这些药物在治疗癌症的同时均有很大的副作用。发展能够在临床广泛使用的天然抗癌药物变得非常迫切。青蒿素最初是从草药青蒿中分离出来的安全有效的抗疟药物,之后被发现具有抗癌作用。它抗癌作用的分子机理主要是通过Fe2+裂解青蒿素的过氧桥结构产生大量的自由基。但是肿瘤细胞中的Fe2+含量与红细胞中相比仍然比较低。因此要提高青蒿素的抗癌效率就必须额外引入Fe2+。此外,由于青蒿素不溶于水,在油中溶解度也不大,导致其生物医学应用受到限制。为了使青蒿素充分发挥抗肿瘤作用,并作为一种天然抗癌药物在临床上得到广泛应用,就必需将青蒿素和Fe2+同时输送到肿瘤病灶,并在细胞内环境下释放,产生大量自由基。

针对上述问题,博士生陈健制备出一种具有多孔结构的Fe3O4@C/Ag@mSiO2纳米粒子。利用该材料的高比表面积,实现了高的药物装载量。该纳米粒子药物载体内的Fe3O4核是由很多尺寸小于10纳米的超顺磁Fe3O4纳米晶体组成的,利用纳米材料的表面效应和肿瘤细胞内溶酶体等酸性微环境,载体粒子就会在肿瘤细胞内同时释放出青蒿素和Fe2+,Fe2+裂解青蒿素中的过氧桥产生自由基,破坏肿瘤细胞的蛋白质、DNA、细胞膜,最终杀死肿瘤细胞。

科研人员用Fe2+试剂盒检测HeLa细胞(亦称实验用增殖表皮癌细胞)内的Fe2+含量,发现在和Fe3O4@C/Ag@SiO2纳米粒子一起培养24小时后,细胞内Fe2+含量从0升高到2.765nmol/L。细胞毒性测试显示被Fe3O4@C/Ag@SiO2纳米粒子装载的青蒿素对肿瘤细胞生长的抑制率比单独青蒿素的抑制率高,而且与目前临床上使用的合成广谱抗癌药物盐酸阿霉素(DOX)在同等测试条件下对肿瘤生长的抑制率相当。

该研究为实现天然药物青蒿素在临床抗肿瘤治疗应用上开辟了一条新途径。

上述研究得到了教育部、国家自然科学基金委大科学装置联合基金项目的支持。

原始出处:

Chen J, Guo Z, Wang HB, Zhou JJ, Zhang WJ, Chen QW.Multifunctional mesoporous nanoparticles as pH-responsive Fe(2+) reservoirs and artemisinin vehicles for synergistic inhibition of tumor growth.Biomaterials. 2014 Aug;35(24):6498-507.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
    2015-06-08 liao1632
  2. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
    2014-08-22 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
    2015-05-07 mei539
  4. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
    2014-11-14 liubm568
  5. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1768982, encodeId=1d641e6898207, content=<a href='/topic/show?id=d7674593e05' target=_blank style='color:#2F92EE;'>#定向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45937, encryptionId=d7674593e05, topicName=定向)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920637977772, createdName=liao1632, createdTime=Mon Jun 08 11:00:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917052, encodeId=1eb0191e052cd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Aug 22 05:00:00 CST 2014, time=2014-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645415, encodeId=52641645415ab, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 16:00:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770486, encodeId=99d21e70486de, content=<a href='/topic/show?id=05fe2665508' target=_blank style='color:#2F92EE;'>#体能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26655, encryptionId=05fe2665508, topicName=体能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80ae38174281, createdName=liubm568, createdTime=Fri Nov 14 14:00:00 CST 2014, time=2014-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049968, encodeId=8cfa2049968ea, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Tue Apr 14 19:00:00 CST 2015, time=2015-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312896, encodeId=5bb6131289605, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486337, encodeId=d868148633ee2, content=<a href='/topic/show?id=865a582869a' target=_blank style='color:#2F92EE;'>#新型药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58286, encryptionId=865a582869a, topicName=新型药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fca58121482, createdName=ms1260584454294838, createdTime=Sun Jul 06 13:00:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10235, encodeId=1c981023592, content=未来青蒿素能变成定向抗癌药就好了,没啥不良反应, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=ping111, createdTime=Fri Jul 04 22:08:00 CST 2014, time=2014-07-04, status=1, ipAttribution=)]
    2014-07-04 ping111

    未来青蒿素能变成定向抗癌药就好了,没啥不良反应

    0

相关资讯

Science:科学家发现导致青蒿素耐药性元凶

4月6日,Science发表的一项研究结果表明,疟疾寄生虫基因组中的一个区域可能是目前最有效的疟疾疗法产生耐药性的“元凶”。这一发现所涉及的耐药性似乎正在东南亚地区蔓延。 在疟疾流行的任何地方,青蒿素已经成为绝对的“主打”疗法。有关青蒿素的耐药性最早于2005年在柬埔寨西部首次被发现。这种耐药性并不会导致青蒿素治疗的彻底失败,但它却减缓了清除患者血液中导致疟疾的恶性疟原虫(Plasmodium

CHM :DNA甲基化暴露疟原虫致命弱点

说到疟疾大多数人想到的只是蚊子,其实疟原虫才是罪魁祸首,蚊子只是携带者。2010年,全球有两亿多人受到疟原虫的感染,其中约六十六万人死亡。更令人头疼的是,这种寄生虫对青蒿素也显示出了抗性,青蒿素曾是治疗感染者的最有效药物。 现在,加州大学的研究人员发现了疟原虫的潜在弱点。研究显示,基因组中的低水平DNA甲基化,对于寄生虫的生存非常关键。文章发表在Cell旗下的Cell Host

PLOS ONE:我国青蒿素类化合物抗肿瘤机制新进展

随着我国科学家凭借对青蒿素类药物的研究获得2011年国际拉斯科临床医学大奖,青蒿素及其衍生物再度成为举世瞩目的明星分子,其中双氢青蒿素(DHA)是青蒿素的主要代谢产物和活性最强的一种衍生物。近年来,王慧研究组对青蒿素类化合物的抗肿瘤功能及机制开展了多项研究,已发现青蒿素及其衍生物对卵巢癌、肝癌的抗癌效果并探讨了其作用机制。本研究中,该组巴乾等研究人员发现,DHA能造成肿瘤细胞铁元素的缺乏、降低铁元

PLoS ONE:左建平等青蒿素衍生物治疗系统性红斑狼疮研究再获进展

系统性红斑狼疮 (systemic lupus erythematosus, SLE)是自身免疫介导的、多系统累及的致死性自身免疫病。多年来,由于受病理机制复杂、治疗靶点缺乏、相关疾病动物模型周期过长等因素的制约,SLE治疗药物的研究进展缓慢。 中科院上海药物研究所左建平研究员课题组多年来致力于SLE治疗药物的研究,并取得了一定的研究成果。水溶性青蒿素衍生物SM934作为治疗SLE候选新药,

Nature:对青蒿素有抗药性的疟疾的一个标记

青蒿素抗药性在所分离出的东南亚疟疾病原体“镰刀形疟原虫”中的传播,可能会葬送为在全世界根除这种疾病所做努力。监测抗药性这一重要工作一直受阻于缺少一个分子标记。 现在,Frédéric Ariey及同事识别出了“镰刀形疟原虫”青蒿素抗药性的一个主要决定因子,它也许能提供这样一个标记。他们发现,该寄生虫的PF3D7_1343700 kelch propeller domain (K-13 prope